Pasithea Therapeutics Corp. KTTA 深 滬

美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级

今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元

06-17 11:32

HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.

06-16 23:36

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics Corp. has amended its Phase 1/1b clinical trial protocol for PAS-004 in NF1 patients with plexiform neurofibromas (PN). The updates include adding two higher dose levels (24mg and 32mg), allowing backfilling of completed dose cohorts, and extending the treatment period to 18 months. Additional MRI scans and detailed tumor measurements will be included. The company has completed enrollment and dosing for initial cohorts (4mg,...

06-16 11:00

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

Pasithea Therapeutics Corp. will participate in the Children's Tumor Foundation's 2026 NF Conference in Denver, Colorado, to engage with the NF1 community following FDA Fast Track and Rare Pediatric Disease Designations for its lead treatment candidate PAS-004. The company aims to develop safer, long-term therapies for NF1 patients and encourages participants to contact them in advance for meetings. PAS-004 is a next-generation macrocyclic MEK in...

06-15 11:02

Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145326

05-30 01:52

Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate

Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.45) by 73.33 percent. This is a 92.55 percent increase over losses of $(1.61) per share

05-16 06:22

Pasithea Therapeutics appoints chief medical officer

Pasithea Therapeutics (KTTA) said on Monday it appointed Kartik Krishnan as chief medical officer as it advances its lead candidate, PAS-004, which is a next-generation MEK inhibitor Krishnan will ove...

05-04 20:34

美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价

今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元

04-21 11:25

Pasithea Therapeutics Wins FDA Rare Pediatric Disease Tag For NF1 Drug Affecting ~115,000 Americans

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and

04-20 19:21

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

04-20 11:01